"Dr. Lichtenfeld will play a critical role in continuing to shape and inform TrialJectory's offerings for cancer patients throughout the country, and across the globe," said TrialJectory CEO and Co-Founder Tzvia Bader. "He understands how, through harnessing the power of technology, we can enable patients to take back control of their care and find advanced new treatments that are right for them. Furthermore, Dr. Lichtenfeld's vast experience in preventing and detecting cancer early, improving patients' quality of life and keeping his finger on the pulse of emerging cancer science and trends over the years will significantly help TrialJectory to provide patients with the tools that they need to successfully navigate their treatment journey."
Dr. Lechtenfeld has more than 40 years of experience delivering cancer care across a range of research and care aspects. He is a board-certified oncologist and internist, and former Deputy Chief Medical Officer for the American Cancer Society.
"Given our shared mission of empowering cancer patients with transformational new technology, I am eager to join the TrialJectory team so that I can leverage my unique skill set to support their growth," said Dr. Lichtenfeld. "Throughout my career, I've always actively sought out opportunities where I thought that I could make a meaningful impact on patients' cancer journeys to improve outcomes and the quality of their lives. I look forward to helping bring this truly innovative AI platform into the hands of patients in need all over the globe at this pivotal time in TrialJectory's evolution."